# Protara Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Protara Therapeutics, Inc.). ## Overview Protara Therapeutics, Inc. is a New York-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline centers on TARA-002, an investigational cell therapy, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, with development activities primarily in the United States. ## Products & services • TARA-002 cell therapy for NMIBC • TARA-002 for lymphatic malformations • IV Choline Chloride for patients on parenteral support • Clinical development and regulatory advancement of pipeline assets - **TARA-002 oncology program** (50%) — Investigational cell therapy being developed for non-muscle invasive bladder cancer and other oncology uses. - **TARA-002 rare disease program** (30%) — Development of TARA-002 for lymphatic malformations and related rare disease indications. - **IV Choline Chloride** (20%) — Investigational intravenous choline replacement therapy for patients receiving parenteral support. - TARA-002 cell therapy for NMIBC - TARA-002 for lymphatic malformations - IV Choline Chloride for patients on parenteral support - Clinical development and regulatory advancement of pipeline assets ## Customers Protara does not yet sell approved products, so its direct customers are future patients, physicians, and treatment centers that would use its therapies if approved. Its current stakeholders are clinical investigators, hospitals, and specialty care providers participating in trials for bladder cancer, lymphatic malformations, and parenteral support-related conditions. - **NMIBC patients and urologists** (primary) — Patients with non-muscle invasive bladder cancer and the urologists who would prescribe intravesical therapy if TARA-002 is approved. - **Rare disease patients and pediatric specialists** (primary) — Patients with lymphatic malformations and related maxillofacial cysts treated by pediatric surgeons and specialty clinicians. - **Parenteral support patients and hospital clinicians** (secondary) — Patients receiving nutrition and fluids through parenteral support who could use IV Choline Chloride if approved. - **Clinical trial investigators** (primary) — Hospitals and research centers that enroll patients, administer study drug, and generate clinical data for the pipeline. - Future NMIBC patients and urologists - Pediatric and specialty clinicians treating lymphatic malformations - Hospitals and infusion centers using parenteral support - Clinical trial sites and investigators - Specialty oncology and rare disease treatment centers ## Geography Protara is headquartered in New York, and its development programs are managed from the United States. The company has secured worldwide rights to TARA-002 excluding Japan and Taiwan, so its commercial opportunity is global even though current operations are centered in U.S.-based clinical development. - Headquartered in New York City - Clinical development managed from the United States - Worldwide rights to TARA-002 exclude Japan and Taiwan - Future commercialization could extend beyond the U.S. - Current operations are primarily U.S.-based ## Strategy Protara’s strategy is to advance TARA-002 through clinical development in NMIBC and lymphatic malformations while preserving optionality for other rare disease uses. It is also developing IV Choline Chloride as a separate pipeline asset, using clinical data, regulatory progress, and intellectual property to build future commercialization opportunities. - **Advance TARA-002 clinical programs** (short-term) — Clinical proof-of-concept is the main value driver for a company with no approved products. - **Build regulatory and commercial optionality** (medium-term) — Successful approvals would create the basis for future partnering or commercialization. - **Protect pipeline economics through IP** (long-term) — Patent protection supports exclusivity in competitive oncology and rare disease markets. - Advance TARA-002 in NMIBC - Complete and expand lymphatic malformation development - Develop IV Choline Chloride for parenteral support patients - Use clinical data to support regulatory filings - Protect and extend intellectual property around the platform ## Risks Protara is exposed to the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and the need for ongoing external financing. Because it relies on third-party manufacturers and contractors, supply, quality, and execution issues can also disrupt development timelines and future commercialization. - **Clinical development failure** [critical] — The company’s value depends on positive data from TARA-002 and IV Choline Chloride trials. - **Regulatory approval risk** [high] — Neither product candidate has FDA or other regulatory approval, so commercialization is not assured. - **Financing risk** [high] — The company has no current revenue and must fund ongoing R&D and trials externally. - **Third-party manufacturing and supply risk** [high] — Clinical and future commercial supply depend on outside contractors and sole-source vendors. - **Competitive risk** [medium] — Established therapies and better-capitalized developers compete in NMIBC and rare disease markets. - No approved products and no product revenue history - Clinical trial failure could eliminate pipeline value - Regulatory approval is uncertain for both programs - Third-party manufacturing and supply dependence - Competition from larger biotech and pharma companies ## Accounting As a clinical-stage biotech, Protara’s most important accounting judgments are in research and development accruals, where trial and vendor costs must be estimated before invoices are finalized. Stock-based compensation, prepaid R&D, and other accruals can materially affect quarterly operating expense timing, while the absence of product revenue means results are driven mainly by expense recognition and investment income. - **Research and development prepaid and accrued expenses** — Can shift quarterly R&D expense and operating loss - **Stock-based compensation** — Affects operating expenses and reported losses - **Investment income on cash and marketable securities** — Can partially offset operating losses - R&D prepaid and accrued expenses require estimation - Clinical trial vendor accruals affect period expense timing - Stock-based compensation is a meaningful operating expense - No product revenue means expense timing drives results - Interest and investment income affect other income, net --- *Last updated: 2026-04-29T04:49:55.699725+00:00*